{"id":"chlorquinaldol","rwe":[{"pmid":"41485094","year":"2026","title":"Perilla frutescens seeds enhance lamb immunity and antioxidant capacity via the microbiota-gut-liver-muscle axis.","finding":"","journal":"Journal of animal science and biotechnology","studyType":"Clinical Study"},{"pmid":"40298634","year":"2025","title":"GSH-Responsive Nano-Photosensitizer for Potentiating Photodynamic Therapy Through Multi-Pronged Synergistic Upregulation of Ferroptosis Sensitivity.","finding":"","journal":"Antioxidants (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"39701924","year":"2024","title":"Extinguishing the flames of inflammation: retardant effect of chlorquinaldol on NLRP3-driven diseases.","finding":"","journal":"Molecular medicine (Cambridge, Mass.)","studyType":"Clinical Study"},{"pmid":"39345816","year":"2024","title":"Chlorquinaldol Alleviates Lung Fibrosis in Mice by Inhibiting Fibroblast Activation through Targeting Methionine Synthase Reductase.","finding":"","journal":"ACS central science","studyType":"Clinical Study"},{"pmid":"38247554","year":"2024","title":"Transferrin-inspired iron delivery across the cell membrane using [(L(2)Fe)(2)(μ-O)] (L = chlorquinaldol) to harness anticancer activity of ferroptosis.","finding":"","journal":"Dalton transactions (Cambridge, England : 2003)","studyType":"Clinical Study"}],"tags":[{"label":"Standardized Chemical Allergen","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D08AH02","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"chloquinan","offLabel":[],"synonyms":["chlorquinaldol","chloquinan","chlorchinaldin","chlorchinaldol","chlorguinaldon"],"timeline":[],"aiSummary":"Chloquinan (Chlorquinaldol) is a standardized chemical allergen classified as a small molecule. It is used to treat various skin conditions, although its exact target and approved indications are unknown. The commercial status of Chloquinan is unclear, and it may be patented or available as a generic medication. Key safety considerations include potential allergic reactions and interactions with other medications. Further research is needed to fully understand its pharmacological properties and clinical applications.","approvals":[],"brandName":"Chloquinan","ecosystem":[],"mechanism":{"target":"Botulinum neurotoxin type A","modality":"Small Molecule","drugClass":"Standardized Chemical Allergen","explanation":"Imagine your immune system is like a security guard that normally only reacts to real threats. Chloquinan tricks the security guard into thinking there's a threat, causing it to react and help clear up the skin condition. This reaction is what helps to treat the condition, but it can also cause some side effects.","oneSentence":"Chloquinan works by inducing an allergic reaction on the skin, which helps to treat certain skin conditions.","technicalDetail":"Chloquinan is a small molecule that acts as a hapten, a molecule that becomes immunogenic only after it has been bound to a larger molecule. It is thought to work by binding to skin proteins and inducing an immune response, leading to the activation of immune cells and the production of inflammatory mediators."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3095","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CHLORQUINALDOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHLORQUINALDOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:35:50.160783","biosimilars":[],"competitors":[{"drugName":"oxyquinoline","drugSlug":"oxyquinoline","fdaApproval":"","relationship":"same-class"},{"drugName":"clioquinol","drugSlug":"clioquinol","fdaApproval":"","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"chlorquinaldol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"oxyquinoline","brandName":"oxyquinoline","genericName":"oxyquinoline","approvalYear":"","relationship":"same-class"},{"drugId":"clioquinol","brandName":"clioquinol","genericName":"clioquinol","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01153958","phase":"PHASE4","title":"Colposeptine for the Treatment of Bacterial Vaginosis","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2010-07","conditions":["Vaginosis, Bacterial"],"enrollment":133,"completionDate":"2010-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000166918","NDDF":"002899","UNII":"D6VHC87LLS","CHEBI":"CHEBI:74500","INN_ID":"215","RXNORM":"2407","UMLSCUI":"C0008292","ChEMBL_ID":"CHEMBL224325","KEGG_DRUG":"D07208","DRUGBANK_ID":"DB13306","PUBCHEM_CID":"6301","SNOMEDCT_US":"255863008","MESH_DESCRIPTOR_UI":"D002750"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":62,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"D08AH02","allCodes":["D08AH02","G01AC03","P01AA04","R02AA11"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan 4","pmid":"41485094","title":"Perilla frutescens seeds enhance lamb immunity and antioxidant capacity via the microbiota-gut-liver-muscle axis.","journal":"Journal of animal science and biotechnology"},{"date":"2025 Mar 28","pmid":"40298634","title":"GSH-Responsive Nano-Photosensitizer for Potentiating Photodynamic Therapy Through Multi-Pronged Synergistic Upregulation of Ferroptosis Sensitivity.","journal":"Antioxidants (Basel, Switzerland)"},{"date":"2024 Dec 19","pmid":"39701924","title":"Extinguishing the flames of inflammation: retardant effect of chlorquinaldol on NLRP3-driven diseases.","journal":"Molecular medicine (Cambridge, Mass.)"},{"date":"2024 Sep 25","pmid":"39345816","title":"Chlorquinaldol Alleviates Lung Fibrosis in Mice by Inhibiting Fibroblast Activation through Targeting Methionine Synthase Reductase.","journal":"ACS central science"},{"date":"2024 Feb 13","pmid":"38247554","title":"Transferrin-inspired iron delivery across the cell membrane using [(L(2)Fe)(2)(μ-O)] (L = chlorquinaldol) to harness anticancer activity of ferroptosis.","journal":"Dalton transactions (Cambridge, England : 2003)"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}